Burden of illness in patients with treatment refractory myasthenia gravis
- PMID: 29486521
- DOI: 10.1002/mus.26114
Burden of illness in patients with treatment refractory myasthenia gravis
Abstract
Introduction: This study assessed the clinical burden of refractory myasthenia gravis (MG), relative to nonrefractory MG.
Methods: Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.
Results: Compared with nonrefractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% vs. 6.1%; P < 0.001) and at least one exacerbation (71.2% vs. 32.4%; P < 0.001) over a 1-year period. Refractory patients were also significantly more likely to be hospitalized and/or have an ER visit than nonrefractory patients and non-MG controls (P < 0.001 for all).
Discussion: Refractory MG patients have significantly greater clinical burden and are more likely to utilize intensive healthcare resources than nonrefractory patients. Furthermore, refractory patients may be at greater risk of crises throughout the disease course than previous studies have suggested. Muscle Nerve, 2018.
Keywords: burden; myasthenia gravis; myasthenic crises; myasthenic exacerbations; refractory; utilization.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.J Clin Neuromuscul Dis. 2020 Sep;22(1):11-21. doi: 10.1097/CND.0000000000000301. J Clin Neuromuscul Dis. 2020. PMID: 32833720 Free PMC article.
-
Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample.J Clin Neurol. 2019 Jul;15(3):376-385. doi: 10.3988/jcn.2019.15.3.376. J Clin Neurol. 2019. PMID: 31286711 Free PMC article.
-
A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis.BMC Neurol. 2022 May 9;22(1):172. doi: 10.1186/s12883-022-02692-4. BMC Neurol. 2022. PMID: 35534810 Free PMC article.
-
Understanding the burden of refractory myasthenia gravis.Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30854027 Free PMC article. Review.
-
Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.Neurol Sci. 2022 Apr;43(4):2271-2276. doi: 10.1007/s10072-021-05823-w. Epub 2022 Jan 18. Neurol Sci. 2022. PMID: 35039987 Free PMC article. Review.
Cited by
-
Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.J Clin Neuromuscul Dis. 2020 Sep;22(1):11-21. doi: 10.1097/CND.0000000000000301. J Clin Neuromuscul Dis. 2020. PMID: 32833720 Free PMC article.
-
Healthcare resource use in myasthenia gravis: a US health claims analysis.Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221150327. doi: 10.1177/17562864221150327. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36710723 Free PMC article.
-
Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study.J Korean Med Sci. 2021 Oct 11;36(39):e242. doi: 10.3346/jkms.2021.36.e242. J Korean Med Sci. 2021. PMID: 34636500 Free PMC article.
-
Myasthenia gravis: understanding treatment patterns and direct medical costs in the Czech Republic.Orphanet J Rare Dis. 2024 Dec 20;19(1):472. doi: 10.1186/s13023-024-03504-3. Orphanet J Rare Dis. 2024. PMID: 39707529 Free PMC article.
-
Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis.Front Neurol. 2020 Dec 23;11:596382. doi: 10.3389/fneur.2020.596382. eCollection 2020. Front Neurol. 2020. PMID: 33424747 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources